OptimizeRx Corporation (OPRX) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, everyone, and thank you for joining OptimizeRx's second quarter fiscal 2025 earnings conference call. We have with us today Chief Executive Officer Steve Silvestro. He is joined by Chief Financial Officer Ed Stelmack, Chief Legal Officer Marion Odinsford, and Senior Vice President of Corporate Finance, Andrew De Silva. At the conclusion of today's call, I will provide some important cautions regarding the forward-looking statements made by management during today's call. The company will also be discussing certain non-GAAP finance measures, which it believes are useful in evaluating the company's operating results. A reconciliation of such non-GAAP financial measures is included in the earnings release the company issued this afternoon, as well as in the investor relations section of the company's website. I would like to remind everyone that today's call is being recorded and will be made available for replay as an audio recording of this conference call on the investor relations section of the company's website. Now, I would like to turn the call over to OptimizeRx CEO, Steve Silvestro. Mr. Silvestro, please go ahead. Thank you, Operator, and good afternoon to everyone joining today's second quarter 2025 call. Overall, we had a strong second quarter of 2025 with results ahead of both consensus estimates and our internal expectations. Recent momentum has continued with Q2 revenues increasing 55% year over year to 29.2 million, with adjusted EBITDA coming in at 5.8 million, an improvement of over 5 million year over year. Moreover, our contracted revenue continues to increase to more than 30% year over year, which positions us favorably in the second half of 2025. I believe this is a clear indicator that our focus on operational excellence while ensur...